News and Updates

Updated 12/22/22

Weight Loss GLP-1 Coverage Tier Update (effective March 1, 2023)

Effective March 1, 2023, GLP-1 weight loss medications (i.e., Wegovy and Saxenda), will be considered non-preferred brand (tier 3) medications, and require a higher member copay.

If you are interested in using a similar formulary product with a lower copay, please discuss the preferred alternative product(s) listed below with your doctor or pharmacist.

Similar products may include:

  • Phentermine tablets – generic (tier 1), lowest copay
  • Bupropion-naltrexone oral tablets (Contrave) – preferred brand (tier 2), lower copay
  • Phentermine-topiramate oral capsules (Qsymia) – preferred brand (tier 2), lower copay

Pancreatic Enzyme Replacement Drugs Reclassified as of Jan. 1, 2023

Effective Jan. 1, 2023, pancreatic enzyme replacement medications (i.e., Creon, ZenPep, Viokace, Pancreaze, and Pertzye) will be reclassified as medications dispensed through U-M's specialty pharmacy. These medications require special storage and handling, have special administration requirements, necessitate close monitoring, and/or are high cost.

Please note: Copays and prior authorizations will stay the same.

  • Michigan residents: This change will require the use of the Michigan Medicine Specialty Pharmacy for future fills.
  • Non-Michigan residents: This change will require the use of Magellan Rx Specialty Pharmacy or Birdi for future fills. Each of these pharmacies offers free shipping.

These medications are limited to a maximum 34-day supply per fill.